Comparing Tegoprazan and Lansoprazole for Treating Bleeding Peptic Ulcers
A Comparison of The Effectiveness of Tegoprazan and Lansoprazole in Achieving Cure Rates in Patients With Bleeding Peptic Ulcers: A Double-Blind Randomized Trial
NA · Dr Cipto Mangunkusumo General Hospital · NCT06894992
This study is testing whether tegoprazan works better than lansoprazole for healing bleeding peptic ulcers in patients from Indonesia.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 162 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Dr Cipto Mangunkusumo General Hospital (other) |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Jakarta, DKI Jakarta and 1 other locations) |
| Trial ID | NCT06894992 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to compare the effectiveness of tegoprazan versus lansoprazole in healing bleeding peptic ulcers in patients from the Indonesian population. Participants will be randomly assigned to receive either tegoprazan 50 mg or lansoprazole 30 mg daily for two weeks, with endoscopic examinations conducted before and after treatment to assess healing rates. The study will also monitor the safety and occurrence of adverse effects associated with both medications.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with upper gastrointestinal bleeding due to peptic ulcers confirmed by gastroscopy.
Not a fit: Patients with allergies to tegoprazan or lansoprazole, those with gastric or duodenal cancer, or individuals with significant comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a more effective treatment option for patients suffering from bleeding peptic ulcers.
How similar studies have performed: While proton pump inhibitors have been widely studied, the use of potassium-competitive acid blockers like tegoprazan is relatively novel, and this study aims to evaluate its effectiveness compared to established treatments.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects diagnosed with upper gastrointestinal bleeding caused by peptic ulcer through gastroscopic examination Exclusion Criteria: * Allergic to Tegoprazan or Lansoprazole * Diagnosed with gastric or duodenal cancer, pregnant * History of H. pylori infection treatment failure * Presence of comorbidities such as chronic kidney disease or decompensated liver cirrhosis * Alcohol consumption * Undergoing chemotherapy
Where this trial is running
Jakarta, DKI Jakarta and 1 other locations
- Cipto Mangunkusumo National General Hospital — Jakarta, DKI Jakarta, Indonesia (RECRUITING)
- Atma Jaya Hospital — Jakarta, DKI Jakarta, Indonesia (RECRUITING)
Study contacts
- Study coordinator: Mario Steffanus MD
- Email: mario.steffanus@atmajaya.ac.id
- Phone: +6281288002263
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Peptic Ulcer Bleeding, Tegoprazan, Lansoprazole, Peptic Ulcer, Healing Rate